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Abstract 
Background 
Surgical site infections continue to be one of the leading causes of nosocomial infections 
leading to increased patient morbidity and mortality, length of hospital stays and healthcare 
expenditure. Amongst the many pathogens, Staphylococcus aureus is a leading cause and 
many efforts have and continue to be made to reduce their incidence. One such intervention is 
the use of intranasal mupirocin in the preoperative setting to reduce nasal carriage of S. aureus. 
Recent studies suggest there seems to be a benefit to using mupirocin in this manner to reduce 
surgical site infections in cardiac and orthopedic surgical populations. This systematic review 
will address the question of whether such an intervention will reduce surgical site infections in 
non-cardiac and non-orthopedic surgical populations. 
Methods 
 I searched MEDLINE and Embase databases until 05/2015 in order to identify 
prospective randomized controlled trials addressing the use of mupirocin in reducing surgical 
site infections which yielded 162 search results. The studies were selected based on pre-
specified criteria. Included studies were prospective randomized controlled trials comparing 
intranasal mupirocin or intranasal mupirocin and topical chlorhexidine to either standard 
treatment or placebo. The primary outcome I was interested in was the incidence of surgical site 
infections. Other outcomes included incidence of Staphylococcus aureus specific surgical site 
infections, narrative or numerical reports on harms, patient compliance, resistance to mupirocin, 
and mortality rates. I only chose studies that followed patients for a minimum of 30 days 
postoperatively. I performed duplicate exclusions, title, and abstract and full text review in order 
to include 4 studies out of the 162 initial search results. Subsequently, I critically appraised each 
included study in order to perform a risk of bias assessment. I then abstracted study 
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characteristics, patient characteristics, and outcomes using a standardized data abstraction 
table. Lastly, I synthesized the abstracted data as part of my qualitative analysis. 
Results 
 There were no reports of statistically significant reductions in either overall surgical site 
infections or S. aureus specific surgical site infections in the four studies included in this 
systematic review. Reports of resistance to mupirocin were only included in one study. Data on 
adverse reactions were reported in three of the four included studies and mostly consisted of 
narrative reports stating that the treatment regimen was well tolerated. Numerical data on 
incidence of adverse reactions provided in one study were similar in both the treatment and 
control arms. No life threatening adverse reactions were reported in the included studies. Only 
one of the four studies provided numerical data on patient compliance whereas the other 
included studies only provided cursory information on compliance. 
Conclusions 
Given that there were no statistically significant reductions in surgical site infections or S. 
aureus specific surgical site infections in the included studies that used mupirocin alone or a 
combination of both mupirocin and chlorhexidine compared to placebo or standard treatment I 
do not have sufficient evidence to recommend preoperative prophylaxis in non-cardiac and non-
orthopedic surgical populations. However, given that the included studies have limited internal 
and/or external validity and because the same intervention has been shown to be potentially 
beneficial in cardiac and orthopedic surgical populations I also don’t have evidence to 
recommend against it. No conclusions can be drawn regarding resistance or patient compliance 
as only one study reported on these outcomes. Given the limited number of studies addressing 
this question in non-orthopedic and non-surgical patients there needs to be additional 
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randomized controlled trials that are sufficiently powered in these patient populations before 
definitive conclusions can be drawn.  
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Background 
Surgical site infections continue to be one of the most common healthcare associated 
infections (HAIs) and lead to increased length of hospital stay and mortality. According to a 
report by the National Healthcare Safety Network, between January 1, 2006 and December 31, 
2008 a total of 849,659 surgical procedures were reported to be done at 847 hospitals in 43 
states in the United States. Among these, there were 16,147 primary incisional SSIs (1.90%).1  
In order to get a better estimate of the national burden of HAIs a study published by the 
Centers for Disease Control and Prevention (CDC) in the New England Journal of Medicine 
evaluated prevalence of HAI across 183 hospitals in 10 states in 2011. Of the 11,282 patients 
evaluated there were 504 total HAIs of which 110 were SSIs. SSIs at 21.8% (18.4-25.6) were 
ranked number 1, tied with pneumonia also at 21.8% (18.4-25.6) as a cause of HAIs. Amongst 
causative organisms for surgical site infections that were detected S. aureus came in at number 
1 at 18 cases (16.4%), followed by Enterococcus species at 16 case (14.5%).2 
According to this study that utilized the Healthcare Cost and Utilization Projection 
National Inpatient Sample (HCUP NIS) that documented 723,490 surgical hospitalizations and 
6891 SSIs there were 406,730 additional hospital days and additional hospital costs exceeding 
700 million US dollars. Moreover, there were 91,613 additional readmissions for SSI treatments 
that accounted for another 521,933 days of care costing nearly 700 million US dollars. SSIs on 
average extend the length of stay by 9.7 days and increasing the cost of by 20,842 per 
admission.  
The following are their reported incidences of SSIs in various surgical categories (Table 
1). Also given below are the average length of stay (days) and cost per stay (US dollars) (Figure 
1 and Figure 2). 
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Surgical Sub-
specialty 
No. of 
discharges 
No. with SSI Percent with 
SSI 
95% CI 
Neurologic 65066 206 0.32 0.27-0.36 
Cardiovascular 62347 734 1.18 1.09-1.27 
Colorectal 86782 3565 4.11 3.98-4.24 
Breast 31863 63 0.20 015-0.25 
GI 156258 2032 1.30 1.24-1.36 
Orthopedic 52133 132 0.25 0.21-0.30 
OB/GYN 269041 159 0.06 0.05-0.07 
Table 1: Incidence of SSIs in various surgical specialties. 
 
 
Figure 1: Average length of stay (days )among patients with and without SSIs in various 
surgical specialties. 
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Figure 2: Average cost per stay (US dollars) among patients with and without SSIs in various 
surgical specialties. 
However, there exists significant variability in the incidence of SSIs as reported in the 
published literature (Table 2). Regardless of the variability in incidences found in the literature 
the consensus remains that SSIs are a preventable cause of burden and suffering for both the 
patient and the healthcare system. 
Surgical Sub-specialty Range of Incidences 
Neurologic 0.5-29% 
Cardiovascular 0.8-4.7% 
Colorectal 2.6-15% 
Breast 0.4-16.3% 
GI 1.3-15.5% 
Orthopedic 0.6-1.4% 
OB/GYN 1.6-9.6% 
Table 2: Range of incidences of SSIs in various surgical specialties found in the biomedical 
literature. 
  
The CDC classification of SSIs is given in Figure 3 below. 
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Figure 3: CDC definition of Surgical Site Infections 
There are several risk factors for surgical site infections that can be classified into the 
preoperative, perioperative and postoperative categories. 
Preoperative Perioperative Postoperative Other 
 Diabetes mellitus 
control 
 Obesity 
 Tobacco use 
 Use of 
immunosuppressants 
 Length of 
preoperative 
hospitalization 
 Wound class 
 Length of 
surgery 
 Shaving of hair 
 Hypoxia 
 Hypothermia 
 Traffic 
 Hypoxia 
 Hypothermia 
 Diabetes 
mellitus control 
 Wound care 
 Blood 
transfusions 
Age 
 
The development of a surgical site infection is a complex interplay between microbial, 
patient and surgical characteristics. The contamination could occur endogenously or 
exogenously. The greatest likelihood of contamination and thereby risk of infection occurs from 
incision to wound closure which has led to endogenous flora from or near the site of incision 
being the leading cause of SSIs. Exogenous sources of contamination include flora from 
SSIs
Incisional Superficial Only skin and 
subcutaneous tissue
Deep Deep soft tissues 
such as muscle and 
fascial layers
Organ/Space Any part of the 
anatomy other than 
the incsions that 
was opened or 
manipulated during 
the operative 
procedure.
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colonized or infected surgical personnel, the operating theater and surgical instruments. These 
are often much less frequent than an endogenous source of contamination. In the setting of 
contamination the burden of pathogen inoculated intraoperatively determines the risk of the 
patient eventually developing an SSI. Given standard antimicrobial prophylaxis an inoculum of 
greater than 105 microorganism is considered necessary to develop an SSI. However, this 
number can be markedly reduced should a foreign body be placed as part of the operation.3 
Staphylococcus aureus, especially methicillin resistant strains of S. aureus have long 
been source of concern due to its increasing role in surgical site infections. It has been reported 
that S. aureus strains survive in the nares. The strains found in the nares may vary amongst 
patients and even within the same patient across their lifespan. Some patients can be 
intermittent carriers, and others can be non-carriers although the latter group is a minority. 
Carriage of S. aureus has been shown to be positively correlated with an increased incidence in 
surgical site infections. The nasal strains have been isolated from patients developing surgical 
site infections.3 
Although efforts were made to reduce nasal carriage through antimicrobial prophylaxis 
as far back as the 1950s, the efficacy of the agents used were inadequate until the use of 
mupirocin for this purpose in the 1980s.4 Mupirocin, also known as pseudomonic acid or as 
BACTROBAN (trade name), was initially identified in 1887 when Garre et al. reported the 
antagonistic effects of Pseudomonas fluorescens. Subsequently, in 1971, Fuller at al. isolated 
the compound for the first time and reported that it had a wide anti-bacterial spectrum against 
gram positive and negative bacteria, showed low toxicity and that it was bacteriostatic against S. 
aureus and E. coli.5 As the name “pseudomonic acid” could lead to the assumption that the 
compound was an antimicrobial against Pseudomonas species the now generic name of 
mupirocin was adopted.6 
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Mupirocin is available as a cream for external use, and in separate ointment formulations 
for intranasal and external use. Intranasal mupirocin calcium ointment (BACTROBAN) is 
available in single use 1 gram tubes. The safety and effectiveness of mupirocin calcium use for 
greater than 5 days have not been established.  Also, the use of intranasal mupirocin calcium in 
children under 12 years of age has not been established. 
Contraindications to its use include known hypersensitivity to mupirocin or any other 
contents of the nasal ointment. Systemic allergic reactions have been reported in patients. 
Chemically BACTROBAN consists of a calcium salt of mupirocin. The nasal ointment is white to 
off-white in color and contains 2.15% w/w mupirocin calcium which is equivalent to 2% 
mupirocin acid. No evidence of systemic absorption of mupirocin has been demonstrated 
following single or repeated intranasal administrations of 0.2 grams of BACTROBAN nasal 
ointment 3 times dual for 3 to 5 days in healthy adult male subjects.7 
After intravenous administration of mupirocin it is metabolized into monic acid an inactive 
metabolite. The half-life for the former is 20 to 40 minutes and for the latter is 30 to 80 minutes. 
Monic acid, the inactive metabolite, is predominantly excreted renally. Note that the 
pharmacokinetics of mupirocin have not been studied in individuals with renal insufficiency.7 
The antibiotic works as a protein synthesis inhibitor by reversibly binding to bacterial 
isolecucyltransfer-RNA synthetase. It is highly protein bound (/>97%) and is bactericidal at the 
concentrations achieved by topical intranasal administration. However, the effect of nasal 
secretions on the minimum inhibitor concentrations of intranasally applied mupirocin as not 
been determined.7 
As someone interested in pursuing a career in general surgery I had been in search of a 
topic within surgery that I could investigate through my master’s paper. Largely through chance I 
ended up enrolling in a class on Hospital Epidemiology during my MPH year when I was 
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assigned a presentation on prevention of SSIs. As I read through the CDC guidelines on 
preventing surgical site infections I came across mupirocin as a potential prophylactic against 
SSIs. However, the guidelines highlighted the need for randomized clinical trials to address the 
question and therefore made no recommendations with regards to using intranasal mupirocin 
preoperatively to reduce SSIs.8 
Subsequently, when I perused the literature I found several studies and systematic 
reviews since the above mentioned guidelines were published. Moreover, it was fascinating that 
the investigations into the role of S. aureus in nasal carriers and nosocomial infections had 
begun in the 1950s. During my surgical rotations on upper gastrointestinal, plastic or thoracic 
surgery I had never seen or heard of mupirocin being used as prophylactic. As I further 
searched the literature I noticed that most of the literature were in cardiac and orthopedic 
surgical patients and recent systematic reviews on the topic seemed to conclude that intranasal 
mupirocin as a prophylactic was beneficial in these patients groups. However, given my interest 
in general surgery I was curious if the same would apply to other surgical procedures given 
some of the new studies that had been published since the latest systematic review on the 
topic. 
Several systematic reviews have been done on the topic of use of mupirocin in recuing 
nosocomial infections including surgical site infections. A systematic review looking at nine 
RCTs involving 3396 participants concluded that there was a significant reduction in the rate of 
SSIs associated with mupirocin use in nasal carriers RR = 0.55 95% CI 0.34-0.89. However, 
they found that this effect disappeared when including only SSIs caused by S. aureus RR = 
0.63, 95% CI 0.38-1.04 (van Rijen, 2008). Another systematic review addressing the same 
issue, however in carrier and non-carriers concluded that the use of preoperative mupirocin in 
general surgery patients had no effect on the incidence of SSIs. They did not comment on the 
effect of the intervention on SSIs specifically caused by S. aureus (Kallen, 2005).  
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Some systematic reviews have excluded non-carriers whereas others have included 
non-carriers in their systematic reviews. In addition, since the last systematic review was 
published in 2013 a small, yet relevant number of studies have been published in the area that I 
believe warrants another comprehensive systematic review in order to address the question of 
whether mupirocin’s intranasal administration reduces surgical site infections (overall and S. 
aureus specific) in non-orthopedic and non-cardiac surgical patients, and if so whether there is 
evidence for the emergence of mupirocin resistance, compliance rates and adverse reactions. 
Should such an approach significantly reduce infection rates without being outweighed 
by harms as a result of adverse reactions, costs accrued and emergence of resistant strains the 
benefits to both the patients and healthcare system would be substantial given the current 
burden surgical site infections place on both. 
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Methods 
 Through the systematic review I will assess whether the use of mupirocin or a 
combination of mupirocin and chlorhexidine reduces the incidence of surgical site infections in 
non-orthopedic and non-cardiac surgical populations postoperatively. 
Eligibility Criteria 
I adopted a search strategy that would attempt to identify prospective randomized 
controlled trials. I excluded all other study designs especially case series, case controls, and 
studies that used historical controls. I chose to do so as the latter study designs tend to have 
poor internal validity and therefore would reduce the level of certainty in my conclusions. 
The analytic framework in Figure 5 provides an overview of the systematic review and 
Table 4 details the population, interventions, outcomes, and adverse events that guided my 
literature search and subsequent data synthesis and analysis. 
I attempted to identify studies that were done in all ages, and both genders with the 
exposure defined as all types of surgery excluding cardiac and orthopedic procedures. These 
procedures were excluded as the use of mupirocin in these patient populations has been 
suggested to be beneficial in several recent systematic reviews, but not as clearly in the case of 
other surgical subspecialties.9-11 I identified studies that used intranasal mupirocin or a 
combination of mupirocin with chlorhexidine and/or povidone-iodine. I chose this strategy in 
order to increase the sensitivity of my search as I had noted in my background reading that 
several studies employed a combination of intranasal mupirocin along with chlorhexidine or 
povidone iodine applied topically.9,10,12 I did not set strict inclusion criteria for the duration of 
mupirocin usage as I had noticed on initial literature review that different studies had varying 
dosages and frequencies of administrations. Studies employing hospital wide screening 
strategies, preoperative oral antibiotics or intranasal mupirocin as a part of a larger infection 
control package were excluded as I considered these to be different from the intervention that I 
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am interested in leading to possible confounding. I searched for studies that employed either 
standard treatment or placebo as controls. I excluded studies where the comparison group 
received either povidone-iodine or chlorhexidine or preoperative oral antibiotics alone or in 
combination.  
I included studies reporting incidence of surgical site infections (overall and S. aureus 
specific) as my primary outcome. Other outcomes that I considered included the incidence of 
resistance to mupirocin, patient compliance to the mupirocin regimen, and incidence of adverse 
events as a result of preoperative prophylaxis. I did not use strict inclusion criteria with regards 
to definition on SSIs as most studies I had reviewed used the CDC definition with the occasional 
study not making their criteria clear. This systematic review focused on incidence of surgical site 
infections in the postoperative setting as the key outcome. I searched databases until May, 
2015 and did not limit my start date as reports of the role of S. aureus in postoperative 
complications date back to the 1950s.13,14 I included studies that were reporting outcomes 
during the 30 days postoperatively as the CDC definition of a surgical site infection limits the 
time to follow up at 30 days postoperatively except in the case of surgeries that use implants 
when the time period is extended to a year.15 Lastly, I limited my search to studies with full-text 
available in English. 
I attempted to address the following questions in this systematic review. 
1. In patients who are candidates for non-orthopedic and non-cardiac surgical procedures 
does intranasal mupirocin in the preoperative setting reduce the incidence of surgical 
site infections (as defined by the CDC) postoperatively when compared with placebo or 
standard treatment? 
2. In patients who are candidates for non-orthopedic and non-cardiac surgical procedures 
receiving intranasal mupirocin in the preoperative setting what is the incidence of 
reported resistance to mupirocin when compared with placebo or standard treatment? 
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3. In patients who are candidates for non-orthopedic and non-cardiac surgical procedures 
does intranasal mupirocin in the preoperative setting lead to any adverse reactions when 
compared with placebo or standard treatment? 
4. In patients who are candidates for non-orthopedic and non-cardiac surgical procedures 
what is the patient compliance rate associated with regimens of intranasal mupirocin 
when compared with placebo? 
Data Sources and Searches 
I searched MEDLINE and Embase electronic databases for studies published until May 
11, 2015 that were published in the English language. I did not set a cut off for the start date as I 
wanted to include even the earliest articles addressing/related to this topic. Investigations on the 
role of S. aureus in nosocomial infections date back as far as 1959 when Williams et al. in 1959 
studies the association between nasal carrier state of S. aureus and the incidence of 
postoperative complications.13 I conducted the searches with the assistance of an information 
technologist familiar with creating search strings for several extensive systematic reviews done 
by faculty at the University of North Carolina at Chapel Hill. 
I included all peer reviewed publications within the search results. There were several 
search results without abstract that were comments or letters to the editor of various journals. 
These were included at the title review, and abstract review stage. They were excluded at the 
full text review stage but relevant points were made not of if it would inform my critical appraisal 
of the included studies, discussion and conclusions. 
I also contacted Glaxo SmithKline (GSK) to identify any unpublished studies that 
addressed this question and was provided with one study that did not meet the inclusion criteria, 
but did inform my discussion of the results. 
Denny Scaria 
Page 18 of 57 
 
Study Selection 
Search results were initially screened through title review to identify articles that were 
obviously not pertaining to the topic at hand. The inclusion and exclusion criteria were strictly 
applied during the abstract review stage. I included articles that did not have an abstract at this 
stage as I had planned on increasing sensitivity during this portion of the search. Article 
exclusions also occurred at the full text review stage and data abstraction stage but not without 
review of the full text. 
All excluded articles were coded with the following corresponding reasons for exclusion: 
1. Not original research  
2. Ineligible population  
3. Ineligible intervention  
4. Ineligible comparator  
5. Ineligible study design  
6. Review  
7. Ineligible outcome 
I was able to do this using Microsoft Excel 2013. Using this software further allowed me to 
tabulate how many articles were excluded for each reason during abstract and full text review 
stages. 
Quality Criteria 
Risk of bias assessment was done by me using the critical appraisal template developed 
by the United States Preventive Services Task Force (Tables 9-12). Studies were rated as + to 
+++ with + being good and +++ being of poor quality with significant risk for bias. The following 
were incorporated into evaluating for risk of bias – initial comparability of treatment and control 
arm/s, potential for selection and measurement bias and confounding. These helped inform my 
assessments of the results’ internal and external validity. 
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Data Abstraction 
I reviewed all titles, abstracts, full texts and performed data abstraction. As a lot of the 
studies did not provide detailed information on the patient population, intervention, and controls 
in the abstract several studies had to be moved into the full text review stage in order to 
appropriately apply the inclusion/exclusion criteria. 
The following study information was abstracted for all included studies: 
1. Author/s 
2. Published year 
3. Study design 
4. Country 
5. Potential conflict of interest 
6. Study period 
7. Type of surgery 
8. Treatment arm size 
9. Control arm size 
10. Type, dosage and frequency of treatment arm intervention 
11. Type, dosage and frequency of control arm intervention 
12. Definition of SSIs and method of assessment 
13. Period of follow up 
14. Harms assessment done? (Yes/No) 
15. Compliance assessment done? (Yes/No) 
16. Screening for colonization? (Yes/No) 
17. Culture confirmation of SSI pathogen? (Yes/No) 
18. Perioperative care characteristics 
The following information was then abstracted for patient characteristics: 
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1. Mean Age 
2. Percentage of Caucasians 
3. Percentage of Males 
4. Percentage of patients with diabetes mellitus 
5. BMI  
6. Percentage of smokers (current/former) 
7. Percentage of immunosuppressed patients 
8. Length of preoperative stay 
9. Percentage of patients with cancer (proxy of history of chemotherapy/radiation also 
accepted) 
10. Length of surgery 
11. Type of surgery 
The following information was collected with regards to primary secondary outcomes 
1. Study arm sizes 
2. Carriage rate 
3. Incidence of SSI 
4. Incidence of S. aureus specific SSI 
5. Measures of associations reported 
6. Harms assessments 
7. Compliance assessments 
8. Resistance to mupirocin assessments 
Data synthesis and Assessment 
I synthesized my findings for each of the key questions by summarizing the results in 
tables in a numerical or narrative format as seen appropriate for the outcome under 
consideration.  
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Results 
Search results 
A total of 162 results were identified across MEDLINE, Embase and searching through 
references. 51 of these articles were selected for full text review. Of these 4 met all the inclusion 
criteria and were selected for qualitative analysis (Figure 4). Studies were excluded at title 
review, abstract review and full text review for several reasons as detailed in Figure 6. The 
primary reasons for exclusions during the abstract review stage included: not original research, 
ineligible population, ineligible intervention and ineligible study design. I excluded the majority of 
articles during full text review because they were either not original research 
(comments/response to articles) or because the study was done in an ineligible population 
(cardiac or orthopedic surgical patients). 
Description of studies 
All the studies that finally met inclusion criteria were randomized controlled trials (Table 
1).16-19 Only one of the studies was double blinded.16 While two studies were conducted in the 
United States, 16,18 the other two were done abroad in Japan17 and Australia.19 
As mentioned earlier this systematic review aims to review literature within non-
orthopedic and non-cardiac surgical patients. The studies included spanned the following 
surgical specialties: Mohs micrographic surgery,19 head and neck,18 abdominal digestive 
surgery (excluding colorectal and laparoscopic),17 and a combination of specialties 
predominated by non-cardiac surgeries.16 Most of the studies enrolled around or less than 200 
patients in each treatment arm except for one that evaluated a total of 3869 patients.16 All of the 
studies used mupirocin ointment in the treatment arm. However, two of the studies detailed 
using chlorhexidine body washes in addition to intranasal mupirocin ointment. All the studies 
except for one17 used a 5 day preoperative regimen. Frequency of dosing varied between 
studies being anywhere form once daily to three times a day. 
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All studies except for one19 used CDC definitions to identify surgical site infections and 
followed patients for a period of 30 days postoperatively to determine the incidence of surgical 
site infections. Two studies undertook harms assessment and addressed compliance concerns 
with such interventions.16,19 Lastly, three of the studies implemented screening in order to 
identify carriers of S. aureus.18,19 The other two studies looked at both carriers and non-carriers 
and did not perform preoperative screening in order to stratify treatments.16,17 
Risk of bias in included studies 
All four included studies were prospective randomized controlled trials. The studies 
varied in their potential for risk of bias. Given that randomization was performed the potential for 
selection bias was minimal in all four included studies. Moreover given that the comparison 
groups were comparable at baseline this further reduced the likelihood for selection bias. 
However, the primary concern for all four studies included potential for confounding. The reason 
for this being that three out of the four studies did not report on several baseline attributes that 
should have been reported such as diabetes status BMI, smoking, previous surgeries, and other 
comorbidities. The potential for measurement bias was minimal in all but one study given that 
they all used standardized definitions for assessing SSIs. One notable source of measurement 
bias is at the intervention level as compliance was reported in only two out of the four studies 
included in the systematic review. Due to the above reasons I deemed the potential for bias to 
be high in one study, low in another and medium in the remaining two studies. 
Generalizability 
The generalizability of these studies vary significantly. One of the studies report results 
in dermatological surgery patients. Another study reports results in head and neck surgery 
patients. The other two report on a combination of surgical patient populations. Also some of the 
studies did not report on several important baseline characteristics such as BMI, smoking 
status, length of preoperative stay and presence of diabetes mellitus, and use of 
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immunosuppressants questioning the generalizability of these studies to the general population. 
Moreover, two of the four studies were conducted abroad which may limit their generalizability 
to patient populations in the United States. 
Outcomes 
Incidence of Surgical Site Infections and S. aureus specific Surgical Site Infections 
Only one of the two studies that used both mupirocin and chlorhexidine reported on 
overall incidence of surgical site infections postoperatively compared to standard treatment.20 
There was no statistically significant reduction when compared to standard treatment. The other 
study reported on S. aureus specific surgical site infection incidence alone which is mentioned 
below.20  
One of the two studies that employed mupirocin alone in the treatment arm instead of a 
combination of mupirocin and chlorhexidine as mentioned above did not report on overall SSI 
incidence instead reporting S. aureus specific surgical site infection incidence which is reported 
below.21 The other study did not report a statistically significant trend of reduction in surgical site 
infections incidence postoperatively compared to placebo and standard treatment.16 
Only two of the four studies reported S. aureus specific surgical site infection incidence. 
One of them used both mupirocin and chlorhexidine in the treatment arm19 whereas the other 
used mupirocin alone.16 Both of these studies did not report a statistically significant reduction 
compared to placebo or standard treatment. 
Adverse Reactions 
None of the studies included reported life threatening adverse reactions. However, three 
of the four studies mentioned adverse reactions of different kinds.16,18,19 One study limited their 
reporting on harms to mentioning that the treatment was “safe and well tolerated”.19 Another 
study took a similar approach and mentioned that “No patients in the treatment group reported 
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complications with the decolonization protocol”.18 The largest study included in this systematic 
review listed similar complication rates in the treatment and placebo arm at 4.8% each. The side 
effects reported were rhinorrhea and itching at application site. Additionally, the authors note 
that five patients in the study withdrew secondary to adverse effects such as nasal bleeding, 
nasal burning, and headache. One of these patients received mupirocin whereas the other four 
were in the placebo arm.16 
Resistance to Mupirocin 
Only one of the studies provided data on the incidence of mupirocin resistance during 
their study period.16 Four of the isolates from the nares of patients were resistant to mupirocin. 
Three of these isolates were from those in the placebo arm, whereas the other one was from 
the mupirocin arm. 
Patient Compliance 
Only one18 of the four studies provided numerical data on compliance. 2 patients in the 
treatment group (5%) in this study were excluded due to non-adherence to the treatment 
regimen. The authors did not clarify the reasons for non-adherence.  
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Discussion 
Systematic Review Findings 
Incidence of Surgical Site Infections and S. aureus specific Surgical Site Infections 
The latest guidelines on antimicrobial prophylaxis in surgical patients only make 
recommendations regarding the use preoperative mupirocin in cardiac and orthopedic patients. 
The authors suggest that there is enough evidence to provide mupirocin decolonization to all 
candidates for cardiac surgery who are colonized with S. aureus. However, the recommendation 
is not as strong in the case of orthopedic surgery patients with the guidelines suggesting that 
there may be some benefit to using preoperative mupirocin decolonization in elective cases.22,23  
In this systematic review I have found no evidence to support the use of mupirocin to 
reduce surgical site infections in non-cardiac and non-orthopedic surgical populations. However, 
this is not to suggest that there is no benefit to be derived from pre-operative decolonization with 
mupirocin in these patients. Instead, given that there is supporting evidence in cardiothoracic 
and orthopedic surgical populations it is plausible that such an intervention could be beneficial in 
other surgical patients too. 
My primary concern is that several of the studies included maybe underpowered. 
Mupirocin has been approved by the FDA for the eradication of nasal decolonization with MRSA 
in those twelve years and older. All but one of the included studies adopted decolonization 
strategies in accordance with the prescribing information approved by the FDA (twice a day for 
five days). Only one study used it for a period of three days, but the authors increased the 
frequency from two times a day to three times a day. Given that most of the studies adopted a 
decolonization protocol similar to what the FDA has approved, it is unlikely that the lack of 
reduction in surgical site infections was due to ineffective decolonization. 
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Pearl et al. reason that they were not able to detect a reduction in surgical site infections 
likely due to their low incidence in the study population thus under powering their study. 
Moreover, they noted some of the surgical site infections were a result of transmission from 
healthcare workers and/or other patients which wouldn’t be prevented by an intranasal 
mupirocin application.  
Much like Pearl et al., Suzuki et al. did not identify any changes in surgical site infections 
as a result of preoperative decolonization with mupirocin. They suggest that it is possible that 
the study design they adopted may not address the complexity of surgical site infections in 
digestive surgery patients. The authors note that many of the surgical site infections they 
detected were mixed gram negative and gram positive infections. In addition, the study did not 
attempt to stratify participants based on carrier status. S. aureus carrier status has been shown 
to be a significant risk factor in developing surgical site infections. This could have led to further 
under powering of the study. 
Although Tai et al. claim to find a statistically significant reduction in surgical site 
infections in nasal carriers, I do not believe that this is the case given that the calculated relative 
risk contains the null value. Similar to the other three studies included, Shuman et al did not find 
a statistically significant reduction in surgical site infections either. The authors reason that it is 
likely due to the underpowered study design. Additionally, just like Suzuki et al. they did not 
stratify interventions based on S. aureus carrier status. 
The 2008 NICE (National Institute for Health and Care Excellence) guidelines which 
were updated in 2014 recommended against using nasal mupirocin for nasal decolonization 
(even in carriers) citing a lack of sufficient evidence of benefits outweighing harms.24 A recent 
update to these guidelines made no further mention of the use of mupirocin.25 In a set of 
recommendations released in 2011, Alexander et al. briefly mentioned that mupirocin has been 
shown to reduce surgical site infections based on a then recent systematic review.26 However, 
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this particular review involved cardiac, orthopedic and notably non-surgical patients. Therefore, I 
do not believe that this recommendation is applicable to the non-cardiac and non-orthopedic 
surgical populations that my systematic review focuses on.  
As the reader may have noted, the theme underlying the four included studies is that of 
underpowered study designs to detect a plausible reduction in surgical site infections, and/or S. 
aureus specific surgical site infections. As a result I cannot make recommendations for or 
against the preoperative use of intranasal mupirocin to reduce surgical site infections. However, 
it is important to take into account that, Pearl et al. found a statistically significant decrease in 
overall nosocomial infections which between the treatment and control arms. It is plausible that 
the correct question to ask going forward would be the effect of preoperative mupirocin 
decolonization on overall hospital acquired infections rather than surgical site infections alone. 
Adverse reactions 
The manufacturer of intranasal mupirocin (BACTROBAN) Glaxo Smith Kline (GSK) 
studied the adverse reactions as part of another study in 105 subjects in which the intranasal 
mupirocin formulation was applied to the inside of participants’ forearm. 2 (2%) reported 
adverse reactions. These included rash and paresthesia.27 In the prescribing information 
provided with intranasal mupirocin GSK lists the following adverse reactions including systemic 
allergic reactions such as anaphylaxis, urticaria, angioedemal and generalized rash. Other side 
effects include, eye irritation, local irritation and C. difficile associated diarrhea. In foreign clinical 
trials the most common reaction was rhinitis, taste perversion and pharyngitis. In domestic trials 
common reactions included headache, rhinitis, pharyngitis, taste perversion, burning/stinging 
(17%).7  
Although GSK reports no fetal harm in animal studies, intranasal mupirocin safety in 
pregnant mothers has not been established. Moreover, its safety has not been determined in 
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those under twelve. Notably, GSK states that significant systemic absorption has been found in 
the neonatal and premature populations unlike in adults. This could potentially impede the use 
of mupirocin in the preoperative setting in many surgical candidates. 
In this systematic review, I have not come across any reports of systemic allergic 
reactions. However the reader should note that one of the four studies do not provide any 
information and two of the four only provide cursory statements on the matter. The one study to 
provide quantitative information reports equal incidence of adverse reactions (rhinorrhea and 
pruritus at the application site) in both treatment arms. 
Although there seems to be no trend in severe adverse reactions I could not reach any 
conclusions due to the paucity of data on this aspect of mupirocin use in three of the four 
included studies.  
Resistance to Mupirocin 
The mechanism of resistance development is the production of modified isoleucyl-tRNA 
synthetase or acquisition of a new isoleucyl t-RNA synthetase through plasmid transfer. Cross 
resistance to other antibacterial have not been reported yet. In an article discussing resistance 
in S. aureus to mupirocin the authors noted that given detection of in vitro resistance it is quite 
plausible that in vivo resistance was to be expected. They concluded by cautioning that 
“extensive use of mupirocin on the skin without proven clinical indication is unwise.” However it 
should be noted that these recommendation were primarily based on topical rather than 
intranasal use of mupirocin.28  
A recent review on the topic of resistance in S. aureus to mupirocin does not specifically 
make recommendations with regards to use of intranasal mupirocin. However they suggest that 
unrestricted use of the antibiotic has been associated with increased incidents of resistance. 
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They suggest active surveillance in patient populations should mupirocin decolonization be 
adopted on a larger scale.29  
Only one among the four studies included in this systematic review provided quantitative 
reports on the incidents of resistance. The other three studies acknowledge that the use of 
mupirocin could potentially result in resistant strains. However, they minimize the concern by 
citing studies that point out that resistance does not emerge unless the antibiotic is used 
indiscriminately. They conclude that using mupirocin in the preoperative setting is unlikely to 
cause resistance. Although this may very well be the case I believe that it would be advisable to 
incorporate active surveillance for resistance against mupirocin in future studies and 
interventions. 
Patient Compliance 
One of the primary concerns regarding the studies I have included with regards to 
internal and external validity is the degree of patient compliance with the decolonization 
regimen. Only one of the four studies reported qualitative and/or quantitative data on 
compliance. The other studies implied that the patients were adherent through generalized 
statements about there being no adverse reactions to the treatment regimens.  
Therefore it is difficult to for me to draw any conclusions regarding the rate of patient 
compliance from the studies that I have included. This is however an important parameter to be 
included in future studies as this will in turn affect both the internal and external validity of the 
results. 
Limitations of the Review 
I acknowledge that there are several limitations to this systematic review. One of them 
being that study selection was not done through dual review. Lack of dual review could have 
possibly resulted in inclusion/exclusion of articles erroneously for a variety of reasons. However 
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I hope that my meticulous approach utilizing a high sensitivity strategy during title and abstract 
review has minimized this as much as possible. I have not been able to conduct a search of the 
references of articles to identify any studies that may not have been identified in the initial 
search. This could have reduced the sensitivity of the search for studies. Additionally, the 
populations such as dermatological surgery, head and neck surgery, cardiac surgery, 
gynecologic surgery, and general surgery. This limits the external validity of the study 
conclusions further limiting my ability to extrapolate from their conclusions. However, I had to 
adopt this approach as the number of studies in non-orthopedic and non-surgical populations 
are limited.  
Additionally, I had not anticipated that some of the studies would use both mupirocin and 
chlorhexidine in the treatment arm. I share the reader’s concern that this is a different 
intervention compared to mupirocin alone. However, given the limited number of studies in this 
area I decided to approach the outcomes from both treatment strategies in order to identify any 
potential differences in outcomes. 
Implications for Practice 
 Given the limited external validity of the studies that I have included in my systematic 
review it is difficult to come to a conclusion regarding the external application of the results of 
the included studies. The studies vary widely in the patient population enrolled. Moreover 
patients are from very different countries with two studies enrolling patients in the United States, 
another one in Japan and the last one in Australia. It is important to take into consideration that 
the health care systems, medical personnel and infection control practices vary between these 
countries and could account for differences in results should such practices be standardized 
universally. Moreover several of these studies did not report on key baseline attributes 
especially comorbidities which make it difficult to translate the results of this systematic review 
and of the included studies to patients.  
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Although S. aureus has been recognized as a leading cause of surgical site infections it 
is quite possible that between subspecialties leading cause of surgical site infections might vary. 
I believe that studies need to be conducted in specific surgical populations that share common 
causative organisms and mechanisms of infections. An important example of the observation by 
Suzuki et al. that mixed gram negative and positive infections were the predominant surgical 
site infections seen in their study of patients undergoing digestive surgery. Therefore at this 
point I'm not able to recommend the use of mupirocin or against the use of mupirocin in the 
preoperative setting in non-cardiac and non-orthopedic surgical populations in order to reduce 
surgical site infections. 
Implications for Research 
Given the heterogeneous nature of the populations and the interventions employed in 
these studies it is essential that research be conducted in specific subspecialties rather than in 
patient populations from several specialties unless upon stratification they are adequately 
powered. It is important that these studies be adequately power to avoid findings that may be 
clinically meaningful but cannot be adopted due to lack of statistical significance as seen in the 
studies included in this systematic review.  
Moreover future studies need to take into account several confounding factors including 
body mass index, diabetes mellitus status, carrier status, immunosuppressive status, cancer 
status, age, smoking status in order to avoid some of the confounding concerns seen in several 
studies included in the systematic review. Such an approach is essential because the use of 
mupirocin has been concluded to be potentially beneficial in cardiac an orthopedic surgical 
populations and should patients benefit from such a simple intervention with very few adverse 
reactions it would be both lifesaving and cost-saving in the long run. As of now there aren't 
enough studies to provide robust evidence on whether such an intervention would be helpful in 
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surgical populations outside of cardiac and orthopedic populations as shown in my systematic 
review. 
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Figures 
Figure 4: Disposition of Articles 
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Figure 5: Analytic Framework 
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Figure 6: Article Exclusions 
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Tables 
Table 3: Search Strategies 
Searches last updated on: 05/11/2015 
Database Search String Results 
MEDLINE (("surgical wound infection"[MeSH Terms] OR ("surgical"[All Fields] AND "wound"[All Fields] AND 
"infection"[All Fields]) OR "surgical wound infection"[All Fields] OR ("surgical"[All Fields] AND 
"site"[All Fields] AND "infection"[All Fields]) OR "surgical site infection"[All Fields] OR (("surgical 
procedures, operative"[MeSH Terms] OR ("surgical"[All Fields] AND "procedures"[All Fields] AND 
"operative"[All Fields]) OR "operative surgical procedures"[All Fields] OR "surgical"[All Fields]) AND 
site[All Fields] AND ("infection"[MeSH Terms] OR "infection"[All Fields] OR "infections"[All Fields]))) 
AND (("administration"[All Fields] AND "intranasal"[All Fields]) OR "intranasal administration"[All 
Fields] OR ("intranasal"[All Fields] AND "administration"[All Fields]) OR "nose"[MeSH Terms] OR 
"nose"[All Fields] OR "nasal"[All Fields])) AND ("mupirocin"[MeSH Terms] OR "mupirocin"[All Fields] 
OR "chlorhexidine"[MeSH Terms] OR "chlorhexidine"[All Fields] OR "povidone-iodine"[MeSH 
Terms] OR "povidone-iodine"[All Fields] OR ("povidone"[All Fields] AND "iodine"[All Fields]) OR 
"povidone iodine"[All Fields]) AND English[lang]  
 
128 
Embase 'povidone iodine'/exp OR 'chlorhexidine'/exp OR 'pseudomonic acid'/exp OR mupirocin AND 
('intranasal drug administration'/exp OR nasal AND administration OR nose OR nasal OR 
intranasal) AND drug AND administration AND ('surgical infection'/exp OR 'surgical site infections') 
AND [embase]/lim NOT [medline]/lim AND [english]/lim 
 
33 
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Table 4: Inclusion/Exclusion Criteria 
 Inclusion Criteria Exclusion Criteria 
Population  Patients of all ages and genders 
undergoing all types of surgery 
excluding cardiac and orthopedic 
procedures. 
 Cardiac surgery 
 Orthopedic surgery 
Intervention  Intranasal mupirocin application 
alone or in combination with 
chlorhexidine body wash. 
 Studies combining intranasal 
mupirocin with other interventions 
such as screening and/or infection 
control measures. 
 Preoperative oral antibiotics 
Comparator  None or placebo  Use of povidone-iodine or 
chlorhexidine alone in any delivery 
mechanism. 
 Preoperative oral antibiotics 
Outcomes  Incidence of SSI 
 Incidence of S. aureus specific SSI 
 Resistance to mupirocin 
 Compliance 
 Adverse events 
N/A 
Time Period of Included Literature  Until 05/2015 N/A 
Outcome Timing  Within 30 days postoperatively N/A 
Study Designs  Prospective randomized controlled 
trials 
 Case series 
 Case controls 
Language  English  Non-English 
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Table 5: Study Characteristics 
 Tai et al. 2013 Shuman et al. 2012 Suzuki et al. 2003 Perl et al. 2002 
Study 
Design 
Randomized control trial Randomized control trial Randomized control trial  Randomized, double blind, 
placebo controlled trial 
Country Australia United States Japan United States 
Potential 
Conflict of 
Interest 
No information provided One medication donated 
by a biomedical company 
but authors declare no role 
on part of company in 
study. 
No information provided Study supported by 
research grant from 
GlaxoSmithKline (GSK). 
Some authors including 
first author have serves as 
paid lecturers for GSK. 
Study period April 1, 2011 – October 31, 
2011 
NR June 1998 - December 
2000 
April 1995 - December 
1998 
Type of 
Surgery 
Mohs Micrographic 
Surgery (MMS) 
Head and neck Abdominal digestive 
surgery excluding 
colorectal and 
laparoscopic surgery 
Elective and non-
emergency cardiothoracic, 
general, oncologic, 
gynecologic, and 
neurologic surgical 
procedures. 
Treatment 
Arm Sample 
Size 
65 (swab positive) 42 193 2012 (1933 evaluated) 
Control Arm 
Sample Size 
65 (swab positive) 42 202 2018 (1931 evaluated) 
Additional 
control arm 
sample size 
59 (Swab negative) N/A N/A N/A 
Treatment Twice daily intranasal 
mupirocin 2% ointment 
and daily face and full 
body wash with 
chlorhexidine gluconate 
4% aqueous solution for 5 
days pre-operatively 
Mupirocin 2% ointment 
applied intranasally once 
daily  and 2% 
chlorhexidine gluconate 
baths once daily during the 
5 days leading up to 
surgery 
30 mg mupirocin calcium 
hydrate ointment via Q-tip 
swab to each nostril three 
times a day on each of the 
3 days prior to operation 
Cotton swab by heath care 
workers or patients with 
mupirocin twice daily for 
up to 5 days before 
procedure 
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 Tai et al. 2013 Shuman et al. 2012 Suzuki et al. 2003 Perl et al. 2002 
Control No treatment No treatment (MSSA and 
–ve cultures) 
No intranasal mupirocin 
given 
Cotton swab by health 
care workers or patients 
with placebo twice daily for 
up to 5 days before 
procedure 
Assessment 
of SSI 
Not detailed CDC definitions; review of 
medical records 
Blinded assessors using 
CDC definitions 
CDC definitions; three 
blinded physicians 
reviewed records to 
ensure appropriate 
diagnosis of SSIs. 
Period of 
follow up 
Not detailed. Provider 
dependent. 
30 days 30 days 30 days on average. Study 
personnel monitored 
inpatients, and reviewed 
medical records. Also, 
telephone discharged 
patients weekly. Patients 
instructed to contact study 
personnel if signs of 
infection seen. 
Harms 
assessment 
Yes Yes; patient self-report No Yes; study personnel 
interviewed patients. 
Compliance 
assessment 
Yes No No Yes; study personnel 
reviewed medical cards 
and diary cards listing 
dates and times of 
intervention administration. 
Screening 
for 
colonization 
Yes; swab and culture Yes; swab and culture No Yes; swab and culture 
Culture 
confirmation 
of SSI 
pathogen 
Yes “Obtained when 
appropriate” 
Yes Yes 
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 Tai et al. 2013 Shuman et al. 2012 Suzuki et al. 2003 Perl et al. 2002 
Perioperative 
care 
No other antimicrobial 
prophylaxis 
Non-carriers and those 
with MSSA received 
routine preoperative 
antimicrobial prophylaxis. 
Those colonized with 
MRSA received additional 
perioperative antimicrobial 
prophylaxis directed 
against MRSA. 
Detailed in both treatment 
and control arms; 
comparable 
Standard prophylactic 
regimens used when 
appropriate. Cardiac 
surgery candidates had 
chlorhexidine body wash 
the night before and the 
morning of the procedure. 
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Table 6: Patient Characteristics 
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Tai 
et 
al., 
2013 
Total 65 NR 59% NR NR NR NR NR NR NR NR 
Non-carrier 65 NR 57% NR NR NR NR NR NR NR NR 
Carrier Control 67 NR 65% NR NR NR NR NR NR NR NR 
Carrier Tx 64 NR 65% NR NR NR NR NR NR NR NR 
Shu
man 
et 
al., 
2012 
Total 58.1
4 
NR 48 
(57%
) 
10 
(12%) 
NR 49 (58%) NR NR Chemo 10 
(12%) 
314 NR 
Radiatio
n 
19 
(23%) 
Carrier Control 59.7
6 
NR 25 
(60%
) 
5 
(12%) 
NR 29 (69%) NR NR Chemo 6 
(14%) 
323 NR 
Radiatio
n 
11 
(26%) 
Carrier Tx 56.5
2 
NR 23 
(55%
) 
5 
(12%) 
NR 20 (48%) NR NR Chemo 4 
(10%) 
304 NR 
Radiatio
n 
8 
(19%) 
Suzu
ki et 
al. 
2003 
Mupirocin 63 NR 127 
(66%
) 
34 
(18%) 
NR NR NR NR NR NR NR 
Control 52 NR 135 
(67%
) 
42 
(21%) 
NR NR NR NR NR NR NR 
Perl 
et 
al., 
2002 
Total Tx 53.8 
+/- 
16.3 
1873 
(96.9
%) 
979 
(50.6
%) 
307 
(15.9
%) 
28.
9 
+/- 
7.8 
583 
(30.2%) 
198 
(10.2
%) 
0 
d 
1152 
(59.8%) 
376 (19.5%) 230 General 
surgery 
1206 
(62.4) 
1 
d 
420 
(21.8%) 
Neurosurg
ery 
364 
(18.8) 
2-
7 
d 
246 
(12.8%) 
Cardiothor
acic 
363 
(18.8) 
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>/
= 
8d 
109 
(5.7%) 
Total Control 54.2 
+/- 
16.5 
1859 
(96.3
%) 
1016 
(52.6
%) 
322 
(16.7
%) 
29.
0 
+/- 
7.9 
568(29.4%) 208 
(10.8
%) 
0 
d 
1159 
(60.1%) 
378 (19.6%) 230 General 
surgery 
1202 
(62.2) 
1 
d 
412 
(21.4%) 
Neurosurg
ery 
368 
(19.1) 
2-
7 
d 
237 
(12.3%) 
Cardiothor
acic 
361 
(18.7) 
>/
= 
8d 
121 
(6.3%) 
Carrier Tx 50.7 
+/- 
16.1 
432 
(97.3
%) 
233 
(52.5
%) 
65 
(14.7
%) 
29.
6 
+/- 
8.5 
117 
(26.4%) 
43 
(9.7%
) 
0 
d 
263 
(59.2%) 
83 (18.7%) 226 General 
surgery 
282 
(63.5) 
1 
d 
107 
(24.1%) 
Neurosurg
ery 
77 
(17.3) 
2-
7 
d 
56 
(12.6%) 
Cardiothor
acic 
85 
(19.1) 
>/
= 
8d 
18 (4.1%) 
Carrier control 52.0 
+/-
17.4 
430 
(96.2
%) 
246 
(55%
) 
71 
(15.9
%) 
29.
9 
+/-
8.8 
121 
(27.1%) 
42 
(9.4%
) 
0 
d 
264 
(59.2%) 
78 (17.4%) 231 General 
surgery 
272 
(60.8) 
1 
d 
102 
(22.9%) 
Neurosurg
ery 
95 
(21.3) 
2-
7 
d 
64 
(14.3%) 
Cardiothor
acic 
80 
(17.9) 
>/
= 
8d 
16 (3.6%) 
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Table 7: Primary Outcome 
 Study 
Arms 
Participant
s 
Carriage 
Rate 
(number/pe
rcentage) 
SSI 
incidence 
(number/per
centage) 
S. aureus 
specific SSI 
incidence 
Measure of 
Association
  
Mupirocin and Chlorhexidine 
Tai et al. 
2013 
Intentionally 
empty 
738 203 (38%) 32 (4%) 30 (4%)  RR = 0.3 (0.1-1.0) P=0.05 (treated 
carriers vs. untreated carriers) 
 RR b/w treated carriers and non-
carriers was not statistically 
significant 
 Carrier Tx 102 N/A 4 (4%) 4 (4%) N/A 
 Carrier 
Control 
101 N/A 11 (11%) 11 (11%) N/A 
 Non-
carriers 
535 N/A 17 (3%) 17 (3%) N/A 
Shuman 
et al. 
2012 
Intentionally 
empty 
84 26 (31%) 17% 
(calculated) 
Not reported  SSI incidence overall in 
experimental vs control OR = 
0.338 95% CI (0.096-1.177); 
P=0.079 
 S. aureus carriers vs non-
carriers overall OR = 0.64; 95% 
CI = 0.12-19.46; P=0.74 
 Experimental vs control 
overall in carriers OR = 1.54; 
95% CI = 0.12-19.46; P = 0.74 
 Experiment
al (Carriers 
and non-
carriers) 
42 N/A 4 (10) Not reported N/A 
 Control 
(Carriers 
and non-
carriers) 
42 N/A 10 (24) Not reported N/A 
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Mupirocin Only 
Suzuki 
et al. 
2003 
Intentionally 
empty 
395 N/A 50 (13%) 
calculated 
Intentionally 
empty 
 
 Mupirocin 
(carriers 
and non-
carriers) 
193 Intentionally 
empty 
28  (14.5) Not reported Intentionally empty 
 Control 
(carriers 
and non-
carriers) 
202 Intentionally 
empty 
22 (10.9) 
 14.5 vs 
10.94% 
Not reported Intentionally empty 
Perl et 
al. 2002 
 3864 891 (23%) 
calculated 
316 (8.2) Intentionally 
empty 
 S. aureus OR = 4.5 carrier 
placebo vs non-carrier placebo; 
95% CI = 2.47-8.21; P<0.0001 
 Total Tx 1933 447 (23%) 152 (7.9) 43 (2.3)  
 Total 
Control 
1931 444 (23%) 164 (8.5) 46 (2.4)  
 Carrier Tx 444 Intentionally 
empty 
44 (9.9) 16 (3.7)  
 Carrier 
control 
447 Intentionally 
empty 
52 (11.6) 26 (5.9)  
 Non-carrier 
Tx 
1489 Intentionally 
empty 
108 (7.3) 27 (1.8)  
 Non-carrier 
control 
1484 Intentionally 
empty 
112 (7.5) 20 (1.4)  
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Table 8: Other Outcomes 
  
 Harms Compliance Resistance 
Tai et al. 
2013 
“Safe and well tolerated.” Also, 
conducted testing prior to study on 
786 patients to assess adverse 
reactions and no contact dermatitis or 
ocular irritation was noted. 
Patient reported NR 
Shuman 
et al. 
2012 
“No patients in the treatment group 
reported any complications with the 
decolonization protocol.” 
2 (5) excluded due to non-adherence 
in both treatment and control arm 
NR 
Suzuki 
et al. 
2003 
NR NR NR 
Perl et 
al. 2002 
Among 4040 patients randomized 97 
of the 2012 in the treatment arm 
(4.8%) and 96 of the 2018 in the 
placebo group reported side effects of 
rhinorrhea and itching at application 
site. 
Five patients withdrew because of 
adverse effects of nasal bleeding, 
nasal burning and headache. 
Amongst these one received 
mupirocin and four received placebo. 
 
NR Only four isolates resistant to 
mupirocin (three from placebo arm; 1 
from mupirocin arm) 
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Table 9: Critical Appraisal of Perl et al. 2002 
Citation (JAMA style)  Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative 
Staphylococcus aureus infections. N Engl J Med. 2002; 346(24):1871-7. 
Study Question and Research 
Design 
 Does preoperative intranasal application of mupirocin decrease the rate of S. 
aureus infections at surgical sites and S. aureus nosocomial infections? 
 Randomized double blind placebo-controlled trial 
Source Population  Patients undergoing elective and nonemergency cardiothoracic, general, oncologic, 
gynecologic and neurologic surgical procedures at the University of Iowa Hospitals 
and Clinics and the Veteran Affairs Medical Center in Iowa City between April 1995 
and December 1998. 
Study Population (descriptive: 
demographics, eligibility criteria) and 
how chosen (volunteers, recruitment, 
tertiary care clinics, population-
based, etc) 
 Exclusion criteria – allergy to mupirocin or glycerin ester, pregnant or breast 
feeding, participating in another clinical trial, history of S. aureus infection in 
previous month, documented disruption of nasal and facial bones, and insertion of 
permanent central catheters alone. 
o 166 excluded because of not undergoing an eligible operation (49 in 
mupirocin group and 48 in placebo group), received no study medication 
(22 and 26 respectively), or met both exclusion criteria (8 and 13 
respectively). 
 Mostly older White individuals who are overweight and with median of 5 comorbid 
conditions. Majority of patients had a duration of preoperative stay of 1 day or less. 
Initial Comparability of groups (ie, 
randomization or group composition; 
concealment of allocation) 
 Very comparable groups 
 Randomization stratified by surgical service 
 No information on allocation concealment 
Drop outs (no endpoint data), 
adherence, crossovers (attrition, loss 
to follow up) 
 479 dropouts; 249 (12.4%) in the mupirocin group vs. 209 (10.4%) in the placebo 
group.  21 patients did not receive study drug. 
 Swabs on SSIs only performed on 111/152 and 127/164 of mupirocin and placebo 
arm patients respectively. Reason not given. 
Potential for selection bias (+ to +++) 
and explain 
 + 
 Randomization should minimize this; however it was stratified by service making 
the likelihood higher than it would have been otherwise. Also, allocation 
concealment is not reported on in the paper. 
Measurement of exposure, 
intervention, potential confounders, 
and outcomes; reliability and validity 
 Nasal swabs and cultures performed to assess carrier status 
 Swabs and cultures performed to confirm S. aureus infection of wound 
 Blinded assessment of SSI 
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of measurement; how performed, 
blinding 
 CDC definitions employed for SSI 
 Blinded assessment of compliance 
Potential for measurement bias (+ to 
+++) 
 + 
Potential confounders (name and 
describe how each was controlled 
for) 
 Several confounders (age, comorbid illnesses and length of preoperative stay) 
controlled for through randomization 
 Not all surgical sites were swabbed and cultured 
Potential for confounding (+ to +++)  + 
Analysis (intention to treat or other 
adjustment) 
 Intention to treat analysis 
Results: magnitude and direction 
(point estimate; random error or 
precision (confidence interval); 
statistical significance 
 Preoperative and postoperative nasal carriage rates virtually unchanged in placebo 
recipients. 
 S. aureus eliminated in 83.4% of patients receiving mupirocin whereas in only 
27.4% of patients receiving placebo (P<0.001) 
 In non-carriers 5.9% of placebo recipients had S. aureus in their nares 
postoperatively whereas only 1.0% of those who got mupirocin did. 
 438 (11.3%) patients had nosocomial infections. 218 (11.3%) were in the mupirocin 
group and 220 (11.4%) were in the placebo group. 
 SSIs were found in 152 (7.9%) of the mupirocin and 164 (8.5%) in the placebo 
group. 
 S. aureus SSIs were found in 43 (2.3%) of the mupirocin and 46 (2.4%) in the 
placebo group. This is after excluding the patients whose surgical sites were not 
cultured. 
 Risk of S. aureus nosocomial infection in nasal carriers treated with mupirocin vs 
placebo was OR = 0.49 95% CI 0.25-0.92; P=0.02 
 Odds of SSIs amongst placebo recipients in carriers vs non-carriers was 4.5 95% 
CI 2.47-8.21 P<0.001 
Overall judgment of internal validity 
(good, fair, poor) 
 Good 
External validity: applicability to other 
populations 
 Applicable to the population seen at a tertiary medical center, but may not 
necessarily translate to ambulatory procedures. Special care should be taken when 
extrapolating results to specialties that were not represented in this study such as 
orthopedics, dermatologic surgery and head and neck surgery. 
Risk of bias  + 
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Table 10: Critical Appraisal of Suzuki et al. 2003 
Citation (JAMA style) Suzuki Y, Kamigaki T, Fujino Y, Tominaga M, Ku Y, Kuroda Y. Randomized clinical trial 
of preoperative intranasal mupirocin to reduce surgical-site infection after digestive 
surgery. Br J Surg. 2003;90(9):1072-5. 
Study Question and Research Design  Does intranasal mupirocin reduce postoperative sepsis rates, including wound 
infection after digestive surgery compared to the control group receiving no 
treatment? 
 Randomized control trial 
Source Population  Patients undergoing “abdominal digestive surgery” at Kobe University Hospital, 
Japan between June 1998 and December 2000 
Study Population (descriptive: 
demographics, eligibility criteria) and 
how chosen (volunteers, recruitment, 
tertiary care clinics, population-based, 
etc) 
 Older males, with comorbidities of diabetes and liver cirrhosis 
Initial Comparability of groups (ie, 
randomization or group composition; 
concealment of allocation) 
 Comparable with regards to prevalence of diabetes, liver cirrhosis, age and 
gender distribution. 
Drop outs (no endpoint data), 
adherence, crossovers (attrition, loss 
to follow up) 
 No information provided on dropouts or adherence  
Potential for selection bias (+ to +++) 
and explain 
 + 
 Randomization minimizes chances, however, no mention of use of allocation 
concealment 
Measurement of exposure, 
intervention, potential confounders, 
and outcomes; reliability and validity of 
measurement; how performed, blinding 
 No swabs or cultures done preoperatively to assess carrier status 
 Mupirocin calcium hydrat ointment 30 mg administered using Q-tip swab to each 
nostril three time a day on each day of the 3 days before the operation. 
 Control group received no treatment. 
 SSI diagnosed based on CDC definitions by a team of digestive surgeons and 
radiologists who were blinded. 
Potential for measurement bias (+ to 
+++) 
 + 
 Unlikely, but possible given minimal information on adherence or compliance to 
mupirocin regimen. 
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Potential confounders (name and 
describe how each was controlled for) 
 Prevalence of diabetes and liver cirrhosis in patients accounted for 
 Other co-morbidities not mentioned 
 BMI not reported for treatment and control arms 
Potential for confounding (+ to +++)  ++ 
Analysis (intention to treat or other 
adjustment) 
 No information provided 
Results: magnitude and direction (point 
estimate; random error or precision 
(confidence interval); statistical 
significance 
 28 SSI in mupirocin group and 22 in control group with no statistically significant 
difference between them. 
 Most SSI were caused by gram negative organisms 
 10 SSIs with gram positive organisms in mupirocin and 11 in control group. Of 
these, 12 were concomitant infections with gram positive and gram negative 
organisms 
 Gram positive bacterial alone in 4 (2.1%) of mupirocin and 5 (2.2%) of control arm 
Overall judgment of internal validity 
(good, fair, poor) 
 Fair 
 Many confounders not taken into account, minimal measurement bias or selection 
bias. 
External validity: applicability to other 
populations 
 Findings could be generalizable to inpatients undergoing “abdominal and 
digestive surgery.” However, given that carrier status was not determined 
preoperatively conclusions must be drawn with caution. 
Risk of bias  ++ 
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Table 11: Critical Appraisal of Shuman et al. 2012 
Citation (JAMA style) Shuman AG, Shuman EK, Hauff SJ, et al. Preoperative topical antimicrobial 
decolonization in head and neck surgery. Laryngoscope. 2012;122(11):2454-60. 
Study Question and Research Design  Randomized controlled trial 
 Efficacy of preoperative topical decolonization with mupirocin and chlorhexidine in 
reducing SSIs regardless of preoperative decolonization status 
 Determine proportion of patients colonized with MSSA or MRSA preoperatively 
 Independent predictors of SSIs in patients undergoing head and neck surgery 
Source Population  Patients attending preoperative otolaryngology clinic prior to elective head and 
neck surgery requiring admission to the hospital postoperatively. 
Study Population (descriptive: 
demographics, eligibility criteria) and 
how chosen (volunteers, recruitment, 
tertiary care clinics, population-based, 
etc) 
 Mostly older male patients with a current or former history of smoking and prior 
history of surgery. 
 Exclusion criteria included patients undergoing ambulatory procedures known 
hypersensitivity to either mupirocin or chlorhexidine, immunosuppression due to 
underlying illness or medications and a documented preoperative infection 
involving the surgical field. 
Initial Comparability of groups (ie, 
randomization or group composition; 
concealment of allocation) 
 Difference among experimental and control group included higher number of non-
smokers and S. aureus carriers, lower prevalence of history of prior radiation in 
the experimental group.  
 Groups comparable otherwise in terms of age, prior history of chemotherapy, 
prior history of surgery and history of diabetes. 
Drop outs (no endpoint data), 
adherence, crossovers (attrition, loss 
to follow up) 
 Two patients in each group excluded due to non-adherence to study protocol 
 Two patients (one in each group) died within 30 days of surgery due to non-SSI 
related complications and were followed up until then. They were included in the 
analysis. 
 84 of 88 patients in final analysis 
Potential for selection bias (+ to +++) 
and explain 
 Unlikely given randomization and good comparability of experimental and control 
groups at baseline. 
Measurement of exposure, 
intervention, potential confounders, 
and outcomes; reliability and validity of 
measurement; how performed, blinding 
 Study participants underwent elective head and neck surgery 
 Preoperative decolonization with mupirocin 2% ointment applied intranasally each 
day for 5 days leading up to the surgery and 2% chlorhexidine gluconate solution 
 Control group did not undergo topical decolonization 
 SSIs assessed based on CDC definitions during a 30 day postoperative follow up 
period by review of medical records for all patients enrolled in the study. 
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 Wound cultures obtained when appropriate 
Potential for measurement bias (+ to 
+++) 
 ++ 
 Measurement bias unlikely at exposure or intervention but possible at outcome as 
no information given regarding blinding of reviewers of medical records. 
Potential confounders (name and 
describe how each was controlled for) 
 Several confounders matches at baseline including history of diabetes, tobacco 
use, age, and S. aureus carrier status. 
 BMI not included in baseline characteristics 
Potential for confounding (+ to +++)  + 
Analysis (intention to treat or other 
adjustment) 
 Uncertain 
Results: magnitude and direction (point 
estimate; random error or precision 
(confidence interval); statistical 
significance 
 10 (24%) SSIs in control group vs. 4 (10%) in experimental group. However, not 
statistically significant. OR = 0.338; 95% CI 0.096-1.177; P=0.079 
 NNT = 7 
 26 (31%) of all participants were carriers of S. aureus. 
o 20 (24%) carried MSSA and 6 (7%) carried MRSA) 
 S. aureus carrier status not associated w/ increased risk of SSIs. OR = 0.64; 95% 
CI 0.15-2.48; P=0.49 
 Carriers who underwent decolonization did not derive significant benefit from it 
compared to carriers in the control group. OR = 1.54; 95% CI 1.08-52.26; P=0.04. 
 Independent risk factors for SSIs included higher ASA Physical Status 
classification system score, more operative blood loss, and need for operative 
takeback.  
 Statistically non-significant trend seen in those undergoing clean-contaminated 
surgery, with prior history of radiation and/or chemotherapy. 
Overall judgment of internal validity 
(good, fair, poor) 
 Fair 
 Potential for measurement bias, but minimal potential for confounding or selection 
bias. 
External validity: applicability to other 
populations 
 Results may be extrapolated to other elective ENT procedures. However, care 
should be taken when applying results to any other surgical procedures. 
Risk of bias  + 
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Table 12: Critical Appraisal of Tai et al. 2013 
Citation (JAMA style)  Tai YJ, Borchard KL, Gunson TH, Smith HR, Vinciullo C. Nasal carriage of 
Staphylococcus aureus in patients undergoing Mohs micrographic surgery is an 
important risk factor for postoperative surgical site infection: a prospective 
randomized study. Australas J Dermatol. 2013;54(2):109-14. 
Study Question and Research Design  Is there a difference in infection rates between nasal carriers and non-carriers of 
S. aureus after MMS? 
 Does decolonization with mupirocin ointment and chlorhexidine wash reduce 
infection rates in nasal carriers? 
 Prospective randomized non-blinded controlled study 
Source Population  Patients presenting for assessment for MMS between April 1 and October 31, 
2011 at private ambulatory day surgical facility in Perth, Australia. 
Study Population (descriptive: 
demographics, eligibility criteria) and 
how chosen (volunteers, recruitment, 
tertiary care clinics, population-based, 
etc) 
 Mostly older male patients requiring surgery on the ear nose, and cheek with 
primarily skin flap used for repair. 
 Exclusion criteria – already on systemic antibiotics, needing reconstructive 
surgery elsewhere 
Initial Comparability of groups (ie, 
randomization or group composition; 
concealment of allocation) 
 Carriers were randomized (method not mentioned) 
 No mention regarding concealment of allocation or blinding 
 Fairly comparable. However, nasal carriers who underwent decolonization had 
less skin flap repairs, and less direct closures compared to those who did not 
undergo decolonization. Also, the former had less operative sites on the nose. 
Drop outs (no endpoint data), 
adherence, crossovers (attrition, loss 
to follow up) 
 49 dropouts due to “administrative error, need for pre-operative or postoperative 
oral antibiotics for non-dermatological reasons, patients’ refusal to participate m 
the study, difficulties in obtaining a preoperative swab and difficulties in contacting 
patients for decolonization therapy.” 
 No information on drop outs to assess comparability 
Potential for selection bias (+ to +++) 
and explain 
 ++ 
 Dropouts increase the likelihood even though groups were comparable at 
randomization. 
Measurement of exposure, 
intervention, potential confounders, 
and outcomes; reliability and validity of 
measurement; how performed, blinding 
 Swabs and cultures done to assess carrier status 
 Mupirocin and chlorhexidine intervention done only in carriers in the treatment 
arm 
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 “Clinical signs of infection” indicated a wound swab in the postoperative period 
and SSI was not diagnosed without positive culture results. 
 No information provided on blinding 
Potential for measurement bias (+ to 
+++) 
 + 
 Unlikely, but possible given that strict criteria were not developed for surveillance 
postoperatively. Sensitivity depends on provider engagement. 
Potential confounders (name and 
describe how each was controlled for) 
 Age, defect size, number of Mohs stages, anatomic location, and repair type were 
comparable in the groups initially. 
 Other potential confounders not accounted for include BMI, smoking status, 
diabetes mellitus and other comorbid health conditions. 
Potential for confounding (+ to +++)  +++ 
Analysis (intention to treat or other 
adjustment) 
 As treated analysis 
Results: magnitude and direction (point 
estimate; random error or precision 
(confidence interval); statistical 
significance 
 RR = 0.3 (0.1-1.0) P=0.05 (treated carriers vs. untreated carriers) 
 RR b/w treated carriers and non-carriers was not statistically significant [RR=1.2 
(0.4-3.5)] 
 RR = 3.4 (1.6-7.0) P<0.001 (untreated carriers vs non-carriers) 
 NNT 
o 15 carriers receive decolonization to prevent one SSI 
o 53 patients swabbed to prevent one SSI 
Overall judgment of internal validity 
(good, fair, poor) 
 Fair 
 Although there is limited concern for measurement bias the concerns of selection 
bias and confounding remain. 
External validity: applicability to other 
populations 
 The source population is not necessarily representative of other surgical 
populations in terms of age, comorbid conditions or procedures undergone. 
Although, this study could inform studies in other surgical fields the results many 
not necessarily applicable to those populations. 
Risk of bias  +++ 
 
 
